Table 1.
Characteristics of rheumatoid arthritis (RA) patients at baseline and after infliximab therapy.
| Baseline | 6 Months | p Values | |
|---|---|---|---|
| Sex (female/male) | 63/16 | ||
| Age, years | 52.8 (43.3–59.4) | ||
| Disease duration (years) | 9 (5–13) | ||
| No destruction, n (%) | 12 (15.2%) | ||
| Wrist destruction, n (%) | 56 (70.9%) | ||
| Periodontal disease, n (%) | 51 (64.6%) | ||
| DAS28 | 5.1 (4.1–5.7) | 3.5 (2.7–4.3) | <0.0001 |
| ESR (mm/h) | 34 (20–49) | 18 (10–32) | <0.0001 |
| CRP (mg/L) | 18 (7–33) | 7 (2–17) | <0.05 |
| Anti–CCP2 (U/mL) | 97 (9–275) | 43 (5–189) | <0.001 |
| RF IgM (IU/mL) | 38 (11–96) | 22 (6–66) | <0.0001 |
| RF IgA (IU/mL) | 25 (10–61) | 17 (8–47) | 0.0001 |
| MMP–3 (ng/mL) | 90 (40–177) | 45 (24–91) | <0.0001 |
| Anti–P. gingivalis whole extract (AU) | 238 (148–377) | 274 (173–557) | <0.01 |
| Anti–P. gingivalis LPS (AU) | 86 (67–146) | 97 (77–152) | NS |
| Anti–P. intermedia whole extract (AU) | 390 (131–1558) | 436 (246–853) | <0.05 |
Values are indicated as number of patients (%) or median (1st and 3rd quartiles). DAS28: Disease Activity Score 28; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; Anti-CCP2: anti-cyclic citrullinated peptides 2nd generation; RF: rheumatoid factor; MMP-3: Matrix metalloproteinase-3; LPS: lipopolysaccharide; U: unit; IU: international units; AU: arbitrary units, NS: non-significant.